Rakuten Investment Management Inc. Takes Position in Pfizer Inc. $PFE

Rakuten Investment Management Inc. purchased a new stake in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 85,586 shares of the biopharmaceutical company’s stock, valued at approximately $2,181,000.

Several other hedge funds and other institutional investors have also bought and sold shares of PFE. Fiduciary Alliance LLC lifted its stake in Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after acquiring an additional 46,043 shares in the last quarter. Vista Investment Partners LLC grew its stake in shares of Pfizer by 236.1% in the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after acquiring an additional 48,900 shares in the last quarter. Generali Investments CEE investicni spolecnost a.s. raised its holdings in shares of Pfizer by 76.4% in the third quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after purchasing an additional 47,319 shares during the last quarter. Fort Washington Investment Advisors Inc. OH lifted its position in shares of Pfizer by 11.2% during the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,892,663 shares of the biopharmaceutical company’s stock valued at $48,225,000 after purchasing an additional 190,946 shares in the last quarter. Finally, Ossiam boosted its holdings in Pfizer by 71.2% during the second quarter. Ossiam now owns 5,650,573 shares of the biopharmaceutical company’s stock worth $136,970,000 after purchasing an additional 2,349,058 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PFE shares. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday. TD Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Morgan Stanley reduced their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Finally, UBS Group began coverage on Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $27.88.

Pfizer Stock Performance

NYSE:PFE opened at $25.65 on Friday. The company has a market capitalization of $145.82 billion, a P/E ratio of 14.91 and a beta of 0.47. The business has a fifty day simple moving average of $25.40 and a two-hundred day simple moving average of $25.01. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s payout ratio is 100.00%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: NICE recommended Pfizer’s PARP inhibitor Talzenna for adults with prostate cancer — a UK endorsement that supports incremental oncology revenue and validates Pfizer’s targeted‑therapy strategy. NICE backs Pfizer’s Talzenna for adults with prostate cancer
• Positive Sentiment: Pfizer launched a large Phase 3 lung‑cancer trial positioning its regimen against Merck’s Keytruda — a successful outcome would target a high‑value oncology market and materially boost long‑term growth expectations. Pfizer Takes Aim at Keytruda in New Phase 3 Lung Cancer Study: What Investors Should Know
• Positive Sentiment: Pfizer moved a COPD candidate into a Phase 2/3 trial, strengthening its post‑COVID respiratory pipeline and the company’s addressable market in chronic lung disease. Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline
• Positive Sentiment: Novavax and Pfizer reached a licensing agreement on the Matrix‑M adjuvant — this could reshape Pfizer’s vaccine platform strategy by expanding adjuvant options and serviceable vaccine markets. Novavax inks license agreement with Pfizer
• Positive Sentiment: Early‑stage pipeline progress: PF‑07248144 advanced with a drug–interaction study and PF‑08065010 entered Phase 1 — steady, low‑visibility pipeline work that reduces binary risk over time. Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress
• Neutral Sentiment: Large options flow: traders bought ~446,836 call options (≈+114% vs. typical volume) — indicates short‑term bullish/speculative positioning but not a direct fundamental signal. (Market data)
• Neutral Sentiment: CEO Albert Bourla publicly criticized RFK Jr.’s vaccine views and warned the U.S. risks falling behind China in health research — a strong management stance on science and policy that can influence regulatory/public perception but is not an immediate earnings driver. Pfizer CEO Calls RFK’s Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research
• Negative Sentiment: Investor concerns persist on pricing and post‑COVID revenue sustainability — recent pieces question whether Pfizer’s current valuation reflects secular headwinds and pricing pressure, which helps explain selling pressure despite pipeline news. Is Pfizer (PFE) Pricing Make Sense After Post Covid Slowdown Concerns
• Negative Sentiment: Opinion pieces highlight a debate whether Pfizer is an attractive dividend/value play or a value trap — ongoing skepticism around growth prospects can keep the stock depressed. Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.